Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer

doi:10.3748/wjg.v21.i43.12234

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 43

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14386)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1021

WORD

302

HTML

8156

Figures (1-1)

263

Tables (1-2)

167

Sum=9909

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1000

Download

1157

Sum=2157

Publishing Process of This Article

Item

Count

Browse

1067

Download

1253

Sum=2320

Nov 21, 2015 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (211)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 21, 2015; 21(43): 12234-12248
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12234

Open in New Tab Full Size Figure Download Figure

Figure 1 Extension of overall survival and development of chemotherapy regimens in metastatic colorectal cancer. 5-FU: 5-fluorouracil; LV: Leucovorin; FOLFIRI: Irinotecan, bolus 5-FU/LV and infusional 5-FU; FOLFOX: Oxaliplatin, bolus 5-FU/LV and infusional 5-FU; FOLFOXIRI: Irinotecan, oxaliplatin, bolus 5-FU/LV and infusional 5-FU.

Citation: Fujita KI, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234-12248
URL: https://www.wjgnet.com/1007-9327/full/v21/i43/12234.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i43.12234